GlaxoSmithKline chops up mature drugs portfolio for $3B sale

GlaxoSmithKline ($GSK) may be hitting obstacles all over the world, what with bribery fines and probes, Advair rivals in Europe, and the like. But the U.K. drugmaker has managed to make progress on its plan to offload some of its older products: It's planning to sell off chunks of the portfolio in geographic areas, with Denmark's Lundbeck and India's Lupin are said to be in the running for regional pieces, likely in the U.S. Report

Suggested Articles

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.

Lions Health shared what worked, what campaigns they wish they had created and what they’ll take back home to talk about with their colleagues.

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.